Rigel Pharmaceuticals Inc (RIGL)
25.04
+0.73
(+3.00%)
USD |
NASDAQ |
Nov 21, 16:00
25.11
+0.07
(+0.28%)
After-Hours: 20:00
Rigel Pharmaceuticals Enterprise Value: 439.73M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 439.73M |
| November 20, 2024 | 426.87M |
| November 19, 2024 | 419.82M |
| November 18, 2024 | 399.21M |
| November 15, 2024 | 423.17M |
| November 14, 2024 | 482.36M |
| November 13, 2024 | 481.48M |
| November 12, 2024 | 478.13M |
| November 11, 2024 | 438.14M |
| November 08, 2024 | 387.41M |
| November 07, 2024 | 270.62M |
| November 06, 2024 | 264.28M |
| November 05, 2024 | 254.07M |
| November 04, 2024 | 246.49M |
| November 01, 2024 | 248.75M |
| October 31, 2024 | 238.71M |
| October 30, 2024 | 249.99M |
| October 29, 2024 | 251.22M |
| October 28, 2024 | 254.39M |
| October 25, 2024 | 248.05M |
| October 24, 2024 | 252.80M |
| October 23, 2024 | 255.62M |
| October 22, 2024 | 260.38M |
| October 21, 2024 | 259.50M |
| October 18, 2024 | 264.78M |
| Date | Value |
|---|---|
| October 17, 2024 | 265.31M |
| October 16, 2024 | 273.94M |
| October 15, 2024 | 268.13M |
| October 14, 2024 | 264.96M |
| October 11, 2024 | 270.42M |
| October 10, 2024 | 266.89M |
| October 09, 2024 | 264.78M |
| October 08, 2024 | 275.17M |
| October 07, 2024 | 269.71M |
| October 04, 2024 | 281.16M |
| October 03, 2024 | 281.34M |
| October 02, 2024 | 290.85M |
| October 01, 2024 | 286.97M |
| September 30, 2024 | 283.63M |
| September 27, 2024 | 299.50M |
| September 26, 2024 | 292.11M |
| September 25, 2024 | 292.99M |
| September 24, 2024 | 298.27M |
| September 23, 2024 | 250.94M |
| September 20, 2024 | 252.70M |
| September 19, 2024 | 251.47M |
| September 18, 2024 | 250.41M |
| September 17, 2024 | 251.29M |
| September 16, 2024 | 252.52M |
| September 13, 2024 | 251.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
38.10M
Minimum
Jun 10 2022
797.94M
Maximum
Feb 08 2021
309.03M
Average
257.79M
Median
May 27 2020
Enterprise Value Benchmarks
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
| Oragenics Inc | 2.273M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 12.42M |
| Revenue (Quarterly) | 55.31M |
| Total Expenses (Quarterly) | 41.25M |
| EPS Diluted (Quarterly) | 0.70 |
| Gross Profit Margin (Quarterly) | 85.49% |
| Profit Margin (Quarterly) | 22.46% |
| Earnings Yield | 0.92% |
| Operating Earnings Yield | 2.16% |
| Normalized Earnings Yield | 0.9185 |